- Tytuł:
- Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus.
- Autorzy:
-
Ingen-Housz-Oro S; Department of Dermatology, AP-HP, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94000, Créteil, France. .; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France. .; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France. .; EpiDermE, Université Paris Est Créteil, Créteil, France. .
Schmidt V; University Hospital Basel, Basel, Switzerland.; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Ameri MM; Faculty of Medicine, University of Zurich, Zurich, Switzerland. .; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. .; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland. .
Abe R; Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Brassard A; Department of Dermatology, UC Davis Medical Center, Sacramento, CA, USA.
Mostaghimi A; Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
Paller AS; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Romano A; Oasi Research Institute-IRCCS, Troina, Italy.
Didona B; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; Rare Disease Unit, I Dermatology Division, Istituto Dermopatico Dell'Immacolata, IRCCS, Rome, Italy.Kaffenberger BH ; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; The Ohio State University Wexner Medical Center Division of Dermatology, Upper Arlington, OH, USA.
Ben Said B; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.; Department of Dermatology, CHU Edouard Herriot, Lyon, France.
Thong BYH; Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore.
Ramsay B; Department of Dermatology, University Hospital Limerick, Limerick, Ireland.
Brezinova E; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; First Department of Dermatovenereology, Masaryk University Faculty of Medicine, St. Ann's Faculty Hospital in Brno, Brno, Czech Republic.
Milpied B; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.; Department of Adult and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France.
Mortz CG; Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.
Chu CY; Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan.
Sotozono C; Department of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-Cho, Hirokoji-Agaru, Kawaramach-Dori, Kamigyo-Ku, Kyoto, 602-0841, Japan.
Gueudry J; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.; Department of Ophthalmology, CHU Charles-Nicolle, Rouen, France.
Fortune DG; Department of Psychology, University of Limerick, Limerick, Ireland.
Dridi SM; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.; MICORALIS Laboratory, Department of Periodontology, Faculty of Dentistry, Côte d'Azur University, Saint Roch Hospital, Nice, France.
Tartar D; Department of Dermatology, University of California Davis, Sacramento, CA, USA.
Do-Pham G; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.; Department of Internal Medicine, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
Gabison E; Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.
Phillips EJ; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia.; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Lewis F; St John's Institute of Dermatology, Guy's and St Thomas' Hospital, London, UK.
Salavastru C; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; Department of Paediatric Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Horvath B; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; Department of Dermatology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.
Dart J; Moorfields Eye Hospital NHS Foundation Trust, The UCL Institute of Ophthalmology, London, UK.
Setterfield J; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; Department of Oral Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Newman J; Department of Dermatology, King's College Hospital NHS Foundation Trust, London, UK.
Schulz JT; Division of Burns, Massachusetts General Hospital, Boston, 02114, USA.
Delcampe A; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.; Department of Ophthalmology, CHU Charles-Nicolle, Rouen, France.; Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.; Department of Ophthalmology, CHU Bichat-Claude Bernard, Paris, France.
Brockow K; Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.
Seminario-Vidal L; Department of Dermatology and Cutaneous Surgery, University of South Florida, Tampa, FL, USA.
Jörg L; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.; Division of Allergology and Clinical Immunology, Department of Pneumology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Watson MP; Cornea and External Eye Disease Service, Moorfields Eye Hospital, London, UK.
Gonçalo M; Department of Dermatology, Coimbra University Hospital Center, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Lucas M; Medical School, University of Western Australia, Perth, WA, 6009, Australia.; Department of Immunology, Sir Charles Gairdner Hospital, Pathwest Laboratory Medicine, Perth, WA, 6009, Australia.
Torres M; Allergy Unit, IBIMA-Regional University Hospital of Malaga-UMA, Málaga, Spain.
Noe MH; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Hama N; Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Shear NH; Department of Dermatology, University of Toronto, Toronto, ON, Canada.; Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
O'Reilly P; Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland.
Wolkenstein P; Department of Dermatology, AP-HP, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94000, Créteil, France.; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.
Romanelli P; Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA.
Dodiuk-Gad RP; Dermatology Department, Emek Medical Center, Bruce Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel.; Department of Medicine, University of Toronto, Toronto, Canada.
Micheletti RG; Department of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Tiplica GS; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; 2Nd Department of Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Sheridan R; Burn Service, Boston Shriners Hospital for Children, Boston, MA, USA.; Division of Burns, Massachusetts General Hospital, Boston, MA, USA.; Department of Surgery, Harvard Medical School, Boston, MA, USA.
Rauz S; Academic Unit of Ophthalmology, Birmingham and Midland Eye Centre, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Ahmad S; Moorfields Eye Hospital NHS Foundation Trust, The UCL Institute of Ophthalmology, London, UK.
Chua SL; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; Department of Dermatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Flynn TH; Ophthalmology, Bon Secours Hospital, Cork, Ireland.
Pichler W; ADR-AC GmbH, Bern, Switzerland.
Le ST; Department of Dermatology, UC Davis Medical Center, Sacramento, CA, USA.
Maverakis E; Department of Dermatology, UC Davis Medical Center, Sacramento, CA, USA.
Walsh S; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; Department of Dermatology, King's College Hospital NHS Foundation Trust, London, UK.
French LE; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany.; Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Brüggen MC; ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.; Faculty of Medicine, University of Zurich, Zurich, Switzerland.; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland. - Pokaż więcej
- Źródło:
- Orphanet journal of rare diseases [Orphanet J Rare Dis] 2023 Feb 22; Vol. 18 (1), pp. 33. Date of Electronic Publication: 2023 Feb 22.
- Typ publikacji:
- Journal Article; Research Support, Non-U.S. Gov't
- MeSH Terms:
-
Stevens-Johnson Syndrome */complications
Humans ; Consensus ; Skin ; Disease Progression
Czasopismo naukowe